Amino-aza-adamantane derivatives and methods of use

Details Amino-aza-adamantane derivatives and methods of use Amino-aza-adamantane derivatives and methods of use

2011-03-01

2011-03-01

Desai, Rita J (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S097000, C514S296000

Reexamination Certificate

active

07897766

ABSTRACT:
The invention relates to amine-substituted aza-adamantane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.Radiolabelled compounds useful for evaluating the binding affinity to α7 nicotinic acetylcholine receptors also are described.

REFERENCES:
patent: 4816453 (1989-03-01), Watts
patent: 4950759 (1990-08-01), van Wijingaarden et al.
patent: 4985424 (1991-01-01), van Wijingaarden et al.
patent: 5208028 (1993-05-01), Clement et al.
patent: 5260303 (1993-11-01), Becker et al.
patent: 5280028 (1994-01-01), Flynn et al.
patent: 5399562 (1995-03-01), Becker et al.
patent: 5434151 (1995-07-01), Cai et al.
patent: 5591749 (1997-01-01), Becker et al.
patent: 5604239 (1997-02-01), Becker et al.
patent: 5643917 (1997-07-01), Flynn et al.
patent: 5723472 (1998-03-01), Miyazawa et al.
patent: 5840903 (1998-11-01), Flynn et al.
patent: 5952339 (1999-09-01), Bencherif et al.
patent: 5986100 (1999-11-01), Crooks et al.
patent: 6057446 (2000-05-01), Crooks et al.
patent: 6093724 (2000-07-01), Grewal et al.
patent: 6251916 (2001-06-01), Grewal et al.
patent: 6323194 (2001-11-01), Grewal et al.
patent: 6417359 (2002-07-01), Crooks et al.
patent: 6423842 (2002-07-01), Grewal et al.
patent: 6555550 (2003-04-01), Grewal et al.
patent: 6627648 (2003-09-01), Dull et al.
patent: 2005/0065178 (2005-03-01), Basha et al.
patent: 2005/0101602 (2005-05-01), Basha et al.
patent: 0 227 215 (1987-07-01), None
patent: 0 645 391 (1995-03-01), None
patent: 543954 (1983-04-01), None
patent: 92/15593 (1992-09-01), None
patent: 94/00454 (1994-01-01), None
patent: 94/02482 (1994-02-01), None
patent: 99/51601 (1999-10-01), None
patent: 99/51602 (1999-10-01), None
patent: 00/11001 (2000-03-01), None
patent: 00/71520 (2000-11-01), None
patent: 02/02564 (2002-01-01), None
patent: 03/094831 (2003-11-01), None
patent: 2005/028477 (2005-03-01), None
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim pg. IX of Preface.
Adams, C.E., et al., “Development of the α7 nicotinic cholinergic receptor in rat hippocampal formation”,Dev. Brain Res., 139:175-187 (2002).
Adler, L.E., et al., “Schizophrenia, Sensory Gating, and Nicotinic Receptors”,Schizophrenia Bull., 24(2):189-202 (1998).
Becker, D.P. & Flynn, D.L., “A Short Synthesis of 1-Azaadamantan-4-one and the 4r and 4s Isomers of 4-Amino-1-azaadamantane”,Synthesis, 1080-1082 (1992).
Cordero-Erausquin, M. & Changeux, J.-P., “Tonic nicotinic modulation of serotoninergic transmission in the spinal cord”,PNAS, 98(5):2803-2807 (2001).
Falk, L., et al., “Higher expression of α7 nicotinic acetycholine receptors in human fetal compared to adult brain”,Dev. Brain Res., 142:151-160 (2003).
Flynn, D.L, et al., “New Aza(NOR)Adamantanes are Agonists at the Newly Identified Serotonin 5-Ht4 Receptor and Antagonists at the 5-HT3 Receptor”,Biorg. &Med. Chem. Ltrs., 2(12):1613-1618 (1992).
Friedman, Joseph I., et al., “A Double Blind Placebo Controlled Trial of Donepezil Adjunctive Treatment to Risperidone for the Cognitive Impairment of Schizophrenia”,Biol. Psychiatry, 51:349-357 (2002).
Furniss, B.S., et al., “Practical Organic Chemistry”, 5thEd., Longman Scientific & Technical & John Wiley & Sons, Inc., Table of Contents (1989).
Jonnala, R.R., & Buccafusco, J.J., “Relationship Between the Increased Cell Surface α7 Nicotinic Receptor Expression and Neuroprotection Induced by Several Nicotinic Receptor Agonists”,J. of Neurosci. Res., 66:565-572 (2001).
Kihara, T., et al., “α7 Nicotinic Receptor Transduces Signals to Phosphatidylinositol 3-Kinase to Block A β-Amyloid-induced Neurotoxicity”,J. of Biol. Chem., 276(17):13541-13546 (2001).
Leonard, S., et al., “Smoking and schizophrenia: abnormal nicotinic receptor expression”,Eur. J. of Pharm., 393:237-242 (2000).
Levin, E.D., “Nicotinic Receptor Subtypes and Cognitive Function”,Neuobiol., 53:633-640 (2002).
Liu, Q.-s., et al., “β-Amyloid peptide blocks the response of α7-containing nicotinic receptors on hippocampal neurons”,PNAS, 98(8):4734-4739 (2001).
Poste, G., et al., “Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells”,Methods in Cell Biology, XIV:33-71 (1976).
Bioreversible Carriers in Drug Design Theory and Application, Table of Contents, Pergamon Press (1987).
Rowley, M., et al., “Current and Novel Approaches to the Drug Treatment of Schizophrenia”,J. of Med. Chem., 44(4):477-501(2001).
Sawa, A. & Snyder, S.H., “Schizophrenia: Neural Mechanisms for Novel Therapies”,Mol. Med., 9:3-9 (2003).
Shimohama, S., et al., “Nicotinic α7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage”,Brain Res., 779:359-363 (1998).
Son, J.-H., & Meizel, S., “Evidence Suggesting That the Mouse Sperm Acrosome Reaction Initiated by the Zona Pellucida Involves an αNicotinic Acetylcholine Receptor”,Biol. of Repro., 68:1348-1353 (2003).
Stevens, K.E., et al., “Selective α7-nicotinic agonists normalize inhibition of auditory response in DBA mice”,Psychopharm., 136:320-327 (1998).
Tsuneki, H., et al., “Mouse muscle denervation increases expression of an α7 nicotinic receptor with unusual pharmacology”,J. Physiol., 547(1):169-179 (2003).
Wang, H., et al., “Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation”,Nature, 421:384-388 (2003).
Schildan et al., “Synthesis and Evaluation of Tritium Labelled 10-methylgalanthamine Iodide”,Journal. of Labelled Comp. and Radoipharm. vol. 46(12) 1117-1125 (2003).
Greene, T.W. & Wuts, P.G.M.,Protective Groups in Organic Synthesis, 3rdEd.:Table of Contents (1999).
Heeschen, C., et al., “Nicotine stimulates angiogenesis and prootes tumor growth and atherosclerosis”,Nature Med., 7(7):833-839 (2001).
Heeschen, C., et al., “A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors”,J. of Clin. Inves., 110(4):527-536 (2002).
Hiebl, J., et al., “New synthesis of isoquinoline-3-carboxylates”,Tetrahedron Ltrs., 40:7935-7938 (1999).
Higuchi, T. & Stella, V., “The Chemistry of a Novel 5,5-Diphenylhydantoin Pro-drug”,A.C.S. Symposium Series, 14:154-183, 1975.
Iriepa, I., et al, “Synthesis and structural study of a series of amides derived from 4α- and 4β-amino-1-azaadamantanes as potential 5-HT3receptor antagonists”,J. of Molec. Struct., 509:105-114 (1999).
IUPAC Comm. on Nomenclature of Org. Chem., “Rules for the Nomenclature of Organic Chemistry”,Pure Appl. Chem., Section E:13-30 (1974).
Jacobi, J., et al., “Nicotine Accelerates Angiogenesis and Wound Healing in Genetically Diabetic Mice”,Amer. J. of Pathology, 161(1):97-104 (2002).

Affiliated with

Also associated with

Rating

Amino-aza-adamantane derivatives and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Amino-aza-adamantane derivatives and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amino-aza-adamantane derivatives and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2661063